Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumor: A phase II study of the Spanish Neuroendocrine Tumor Group (GETNE0801).

Castellano, Daniel; Capdevila, Jaume; Salazar, Renato; Sastre, Javier; Alonso, Vicente; Llanos, Marta; García‐Carbonero, Rocío; Abad, Albert; Sevilla, Isabel; Durán, Ignacio

doi:10.1200/jco.2011.29.15_suppl.4113

Cited by 12 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It should be noted that the study was discontinued early on the recommendation of the data and safety monitoring committee because of the greater number of deaths and serious adverse events in the placebo group. The observed PFS was consistent with data from other studies of vascular endothelial growth factor inhibitors in pancreatic NET (Faivre et al 2006;Hobday et al 2007;Kulke et al 2008;Castellano et al 2011;Raymond et al 2011b).…”

Section: Introductionsupporting

confidence: 91%

Quality of life, resource utilisation and health economics assessment in advanced neuroendocrine tumours: a systematic review

Chau

Casciano²,

Willet³

et al. 2013

Eur J Cancer Care (Engl)

View full text Add to dashboard Cite

Neuroendocrine tumours (NET) are often diagnosed at an advanced stage when the prognosis is poor for patients, who often experience diminished quality of life (QoL). As new treatments for NET become available, it is important to characterise the associated outcomes, costs and QoL. A comprehensive search was performed to systematically review available data in advanced NET regarding cost of illness/resource utilisation, economic studies/health technology assessment and QoL. Four rounds of sequential review narrowed the search results to 22 relevant studies. Most focused on surgical procedures and diagnostic tools and contained limited information on the costs and consequences of medical therapies. Multiple tools are used to assess health-related QoL in NET, but few analyses have been conducted to assess the comparative impact of available treatment alternatives on QoL. Limitations include English language and the focus on advanced NET; ongoing terminology and classification changes prevented pooled statistical analyses. This systematic review suggests a lack of comparative economic and outcomes data associated with NET treatments. Further research on disease costs, resource utilisation and QoL for patients with advanced NET is warranted.

show abstract

Section: Introductionsupporting

confidence: 91%

Quality of life, resource utilisation and health economics assessment in advanced neuroendocrine tumours: a systematic review

Chau

Casciano²,

Willet³

et al. 2013

Eur J Cancer Care (Engl)

View full text Add to dashboard Cite

show abstract

“…Dose reduction to sorafenib, 200 mg daily, significantly improved tolerability, with 15% of the patients experiencing grade 3 toxicities (66). The same schedule was tested in a phase II trial in 44 patients with advanced neuroendocrine tumors, with an RR of 9.8% reported; however, 20% of patients developed grade 3 HFS and 15% developed grade 3 asthenia (67). No objective responses were observed when this schedule was used in phase II trials in advanced melanoma and colorectal cancer (68,69).…”

Section: Combining 2 Indirect Inhibitorsmentioning

confidence: 99%

Combining Antiangiogenics to Overcome Resistance: Rationale and Clinical Experience

Moreno

Basu

Molife

et al. 2012

Clinical Cancer Research

View full text Add to dashboard Cite

Antiangiogenic therapies are now well established in oncology clinical practice; however, despite initial optimism, the results of late-phase trials, especially in the adjuvant setting, have largely proved disappointing. In the context of metastatic disease, resistance to antiangiogenic agents arises through a range of mechanisms, including the development of alternative angiogenic pathways. One of the proposed strategies to overcome this resistance is to combine antiangiogenic agents with different mechanisms of action. Earlyphase clinical trials assessing the tolerability and efficacy of different combinations of antiangiogenic drugs, including those that target the VEGF pathway or the angiopoietins, as well as vascular disrupting agents, are increasing in number. An example of this strategy is the combination of sorafenib and bevacizumab, which has elicited major responses in different tumor types, including ovarian carcinoma and glioblastoma. However, overlapping and cumulative toxicities pose a real challenge. This review summarizes the preclinical rationale for this approach and current clinical experience in combining antiangiogenic therapies.

show abstract

“…The Spanish Neuroendocrine Tumor Group (GETNE, Grupo Español de Tumores Neuroendocrinos) conducted a phase II study with the combination of sorafenib and bevacizumab in metastatic NETs [42]. Preliminary results with data from 37 patients yielded a median PFS of 10.0 months and a manageable toxicity profile [42].…”

Section: Limitations and Advances In The Treatment Of Gep-netsmentioning

confidence: 98%

Future perspectives on neuroendocrine tumors

Castellano

Salazar

Raymond

2011

Cancer Metastasis Rev

View full text Add to dashboard Cite

In the last 30 years the incidence and prevalence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) has increased substantially. This could be partly due to improvements in diagnostic imaging, which lead to the incidental diagnosis of asymptomatic cases. However, despite these improvements, patients typically experience long delays before they are diagnosed. In this review, we discuss both the limitations and advances in our understanding of the pathogenesis, molecular and cellular biology, diagnosis, classification, staging, and treatment of GEP-NETs in order to identify which factors could be contributing to the delay in diagnosis and timely treatment of these patients. Within this context, the results from the most relevant clinical trials the available targeted therapies for the treatment of GEP-NETs, such as the "RAD001 in Advanced Neuroendocrine Tumors," will be discussed.

show abstract

Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumor: A phase II study of the Spanish Neuroendocrine Tumor Group (GETNE0801).

Cited by 12 publications

References 0 publications

Quality of life, resource utilisation and health economics assessment in advanced neuroendocrine tumours: a systematic review

Quality of life, resource utilisation and health economics assessment in advanced neuroendocrine tumours: a systematic review

Combining Antiangiogenics to Overcome Resistance: Rationale and Clinical Experience

Future perspectives on neuroendocrine tumors

Contact Info

Product

Resources

About